

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

Nunzia Pharmaceutical Company

1627 West 14th Street, Long Beach, California, 90813
(714) 609-9117
Nunziapharma.com/
SIC code : 2834

Quarterly Report For the Period Ending: June 30, 2022 (the "Reporting Period")

As of June 30, 2022 the number of shares outstanding of our Common Stock was:

434,189,578

As of March 31, 2022 the number of shares outstanding of our Common Stock was:

434,119,578

As of December 31, 2021, the number of shares outstanding of our Common Stock was:

434,119,578

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

Yes: ☐ No: ☒

¹ "Change in Control" shall mean any events resulting in:

- (i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

1) Name and address (es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

Our Company's name is Nunzia Pharmaceutical Company (the "Company"). The Company was incorporated on November 12, 1986, in the state of Utah under the name of Silver Harvest, Inc. In February 1990, the Company amended its Articles of Incorporation to change its name to Viking Capital Group, Inc. In June 2010, the Company amended its Articles of Incorporation to change its name to Arizona Gold and Onyx Mining Company. On February 1, 2018, the Company amended its Articles of Incorporation to change its name to Nunzia Pharmaceutical Corporation.

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

Nunzia Pharmaceutical Company was incorporated on November 12, 1986, in the state of Utah. Our current standing in the state of Utah is "Active"

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

The address(es) of the issuer's principal executive office:

Our principal executive office is located at 1627 West 14th Street, Long Beach, California 90813

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address: ☒

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☐ No: ☒

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

N/A

2) Security Information

Trading symbol:	NUNZ
Exact title and class of securities outstanding:	Class A Common Stock
CUSIP:	67097W102
Par or stated value:	\$0.001

Total shares authorized:	1,000,000,000 as of date: June 30, 2022
--------------------------	---

Total shares outstanding:	434,189,578	as of date: June 30, 2022
Number of shares in the Public Float ² :	13,006,756	as of date: June 30, 2022
Total number of shareholders of record:	<u>648</u>	as of date: June 30, 2022

All additional class(es) of publicly traded securities (if any):

Trading symbol:	_____
Exact title and class of securities outstanding:	_____
CUSIP:	_____
Par or stated value:	_____
Total shares authorized:	_____ as of date: _____
Total shares outstanding:	_____ as of date: _____

Transfer Agent

Name: Nevada Agency and Transfer Company
Phone: 1-775-322-0626
Email: tiffany@natco.com
Address: 50 West Liberty Street, Suite 880

Is the Transfer Agent registered under the Exchange Act?³ Yes: ☒ No: ☐

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

² "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

³ To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: ☐

Shares Outstanding as of Second Most Recent Fiscal Year End:			*Right-click the rows below and select "Insert" to add rows as needed.						
<p><u>Opening Balance</u></p> <p>Date 12/31/2019 Common: 243,519,578</p>									
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
1/15/2020	New issuance	200,9000	Common	\$0.006	Yes	Pacific Advisors, LLC- Brian Volmer has voting control	Consulting	Unrestricted	4a2
8/16/2020	New issuance	200,000	Common	\$0.001	No	Neal Johnson	Merger	Restricted	4a2
8/16/2020	New issuance	200,000	Common	\$0.001	No	Lisa Belesky	Merger	Restricted	4a2
4/26/2021	New issuance	2,000,000	Common	\$0.001	No	Chad Mitsunaga	Merger	Restricted	4a2
4/21/2021	New Issuance	5,000,000	Common	\$0.001	No	Global Wholehealth Partners Rene Alvarez voting control	Marketing agreement	Restricted	144
4/26/2021	New issuance	250,000	Common	\$0.001	No	Nanci King	Merger	Unrestricted	4a2
4/26/2021	New issuance	250,000	Common	\$0.001	No	Eva Lazar	Merger	Unrestricted	4a2
4/26/2021	New issuance	250,000	Common	\$0.001	No	Kevin Lee	Merger	Unrestricted	4a2
4/26/2021	New issuance	7,500,000	Common	\$0.001	No	David Kassab	Merger	5,000,000 shares unrestricted 2,500,000 shares restricted	4a2

4/26/2021	New issuance	7,500,000	Common	\$0.001	No	Jonathan Kassab	Merger	5,000,000 shares unrestricted 2,500,000 shares restricted	4a2
<u>6/7/2021</u>	Cancellation	(9,000,000)	Common	\$0.001	No	Richard Johnson	Merger	n/a	4a2
<u>7/8/2021</u>	New issuance	3,000,000	Common	\$0.001	No	Michael Mitsunaga	Merger	Restricted	4a2
<u>11/24/2021</u>	<u>New issuance</u>	5,000,000	Common	\$0.001	<u>No</u>	Jonathan Kassab	Conversion of debt	Unrestricted	144
<u>11/24/2021</u>	<u>New issuance</u>	5,000,000	Common	\$0.001	<u>No</u>	David Kassab	Conversion of debt	Unrestricted	144
<u>11/24/2021</u>	<u>New issuance</u>	1,250,000	Common	\$0.001	<u>No</u>	Chad Mitsunaga	Conversion of debt	Unrestricted	144
<u>11/24/2021</u>	<u>New issuance</u>	250,000	Common	\$0.001	<u>No</u>	Kevin, Le	Conversion of debt	Unrestricted	144
<u>11/24/2021</u>	<u>New issuance</u>	250,000	Common	\$0.001	<u>No</u>	Nancy King	Conversion of debt	Unrestricted	144
<u>11/24/2021</u>	<u>New issuance</u>	250,000	Common	\$0.001	<u>No</u>	Eva Lazar	Conversion of debt	Unrestricted	144
<u>11/24/2021</u>	<u>New issuance</u>	450,000	Common	\$0.001	<u>No</u>	Ken Bridgman	Conversion of debt	Unrestricted	144
<u>11/24/2021</u>	<u>New issuance</u>	1,000,000	Common	\$0.001	<u>No</u>	Charles Strongo	Conversion of debt	Unrestricted	144
<u>11/24/2021</u>	<u>New issuance</u>	1,000,000	Common	\$0.001	<u>No</u>	Michael Mitsunaga	Conversion of debt	Unrestricted	144
<u>11/24/2021</u>	<u>New issuance</u>	200,000	Common	\$0.001	<u>No</u>	Empire Associates - Jamie Yafa has voting control	Conversion of debt	Unrestricted	144
<u>11/24/2021</u>	<u>New issuance</u>	8,350,000	Common	\$0.001	<u>No</u>	Lionsgate Funding Group Sara Gonzales has voting control	Conversion of debt	Unrestricted	144
<u>12/6/2021</u>	<u>New issuance</u>	75,000,000	Common	\$0.001	<u>No</u>	Lionsgate Funding Group Sara Gonzales has voting control	Services	Restricted	144

<u>12/6/2021</u>	<u>New issuance</u>	25,000,000	Common	\$0.001	<u>No</u>	Lionsgate Funding Group Sara Gonzales has voting control	Services		144
<u>12/6/2021</u>	<u>New issuance</u>	2,500,000	Common	\$0.001	<u>No</u>	Michael Mitsunaga	Services	Restricted	144
<u>12/6/2021</u>	<u>New issuance</u>	2,500,000	Common	\$0.001	<u>No</u>	Michael Mitsunaga	Services	Restricted	144
<u>12/6/2021</u>	<u>New issuance</u>	45,000,000	Common	\$0.001	<u>No</u>	Lionsgate Funding Group Sara Gonzales has voting control	Services	Restricted	144
<u>6/10/2022</u>	<u>New issuance</u>	<u>70,000</u>	Common	\$0.02	Yes	Scott Ford	Private placement	Restricted	144
Shares Outstanding on Date of This Report:									
<u>Ending</u> _____ <u>Balance</u>									
<u>Ending Balance:</u>									
Date 6/30/2022									
Common: 434,189,578									

Example: A company with a fiscal year end of December 31st, in addressing this item for its quarter ended June 30, 2021, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2019 through June 30, 2021 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements: ☒

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____

Use the space below to provide any additional details, including footnotes to the table above:

4) Financial Statements

A. The following financial statements were prepared in accordance with:

- ☒ U.S. GAAP
☐ IFRS

B. The financial statements for this reporting period were prepared by (name of individual)⁴:

Name: **David Natan**
Title: n/a
Relationship to Issuer: Third party Consultant

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance Sheet;
- D. Statement of Income;
- E. Statement of Cash Flows;
- F. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- G. Financial notes; and
- H. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the

⁴ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations") We are a pharmaceutical and nutraceutical company that owns the rights to a drug that treats autism, fragile X, ADHD, and PTSD. We manufacture, market and distribute the drug Nunzia, a drug that is more effective than any drug on the market to treat the symptoms of these diseases. The drug, called Nunzia, acts to increase sensory, social, and daily living skills, as well as attention span, memory retention, focus, comprehension, and learning, all the while decreasing anxiety, stress, fixations, fidgeting, and outside distractions. The current drugs that are used to attempt to control the symptoms of these conditions are largely ineffective. Nunzia is the only drug on the market that effectively treats the symptoms of these wide-ranging medical conditions. NUNZIA is able to reduce the extra synapses which cause anxiety. When there is a rapid firing of synapse and the protein filters of the brain are functional, then anxiety occurs, but no or little affixations, but when the protein filters are not functional or functioning at full capacity, such as the FXMP protein, then anxiety can also produce affixations and other disorders, which are related to affixations or compulsory. We had thought that Fragile X or Autist people did not have the FXMP protein and was the root cause, but after much research, we did conclude that the FXMP protein filter was present, but not functioning at full capacity and functioned at different levels according the individual and therefore the consensus and conclusion was that the different levels of functionality of the FXMP could be the main cause of affixations and compulsory disorders at different levels in the individual. Anxiety Systems and Disorders alone cause various problems, but when coupled with a malfunctioning FXMP protein the problems are exponential. The hippocampus is the part of the brain that is involved in memory forming, organizing, and storing. It is a limbic system structure that is particularly important in forming new memories and connecting emotions and senses, such as smell and sound, to memories. The hippocampus is a horseshoe shaped paired structure, with one hippocampus located in the left-brain hemisphere and the other in the right hemisphere. The hippocampus acts as a memory indexer by sending memories out to the appropriate part of the cerebral hemisphere for long-term storage and retrieving them when necessary. The hippocampus is involved in several functions of the body including: Consolidation of new memory; Emotional Responses Navigation; and Spatial Orientation. NUNZIA works with the Hippocampus part of the brain. The hippocampus is a region of the mammalian brain that shows an impressive capacity for structural reorganization. Preexisting neural circuits undergo modifications in dendritic complexity and synapse number, and entirely novel neural connections are formed through the process of neurogenesis. These types of structural change were once thought to be restricted to development. However, it is now generally accepted that the hippocampus remains structurally plastic throughout life. This article reviews structural plasticity in the hippocampus over the lifespan, including how it is investigated experimentally. The modulation of structural plasticity by various experiential factors as well as the possible role it may have in hippocampal functions such as learning and memory, anxiety, and stress regulation are also considered. Current anti-anxiety drugs are broad acting and usually

ineffective, including such drugs as Valium, Prozac, amphetamines, and anti-psychotics. These drugs are considered “Hit or Miss”, singly or in combination. The quick synapses or misfiring is still occurring, and the affixations, anxiety and or other disorders are still acting out in the brain, but the present drugs have drugged the entire body, like a straight jack. The person still wants to act out on the effects of the synapse and excessive waste proteins being developed creating even more anxiety. The advantage of Nunzia is that it is a targeted Blocker B instead of a broad blocker. With Nunzia, the synapse is not too quick or misfiring, therefore the people do not have the inner need to act out the misfiring, because they are not misfiring, and no anxiety is occurring. There are no other drugs like NUNZIA, which helps so many disorders that are caused or exasperated by anxiety. Thus, in terms of the industry overview, the market is immense, yet, the competition is nonexistence since no other drug is able to target the synapses causing anxiety.

B. Please list any subsidiaries, parents, or affiliated companies.

Cal-Biotech Inc.

C. Describe the issuers’ principal products or services.

Nutraceutical and Pharmaceutical products for people with ASD (Autistic Spectrum of Disorders)

6) Issuer’s Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.
n/a

7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% or more of any class of the issuer’s securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
Michael Mitsunaga	Director President	Long Beach, California	9,320,000	Common	2.1%	
Dr. Shujie Cui	Chief Medical Officer	Long Beach, California	2,500,000	Common	.6%	
Sara Gonzales	CEO, Director	Long Beach, California	5,050,000	Common	1.2%	
Charles Strongo	Former CEO	Anaheim, California	18,975,000	Common	4.4%	
Lionsgate Funding Group, Sara Gonzales has voting control and is also the CEO of Nunzia Pharmaceutical	>5% shareholder	Long Beach, California	289,159,000	Common	66.6%	
Lionsgate Funding Management LLC, Sara Gonzales has voting control and is also the CEO of Nunzia Pharmaceutical	>5% shareholder	Long Beach, California	50,000,000	Common	11.5%	

8) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Accountant or Auditor

Name: BF Borgers CPA PC
Firm: 5400 W Cedar Ave Lakewood, Co 80226
Address 1: _____
Address 2: _____
Phone: 303-953-1454
Email: Ben@bfcpa.us

Investor Relations

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

Name: _____
Firm: _____
Nature of Services: _____
Address 1: _____

Address 2: _____
Phone: _____
Email: _____

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Sara Gonzales certify that:

1. I have reviewed this Quarterly Report of Nunzia Pharmaceutical Company
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

8-12-2022 [Date]

/s/Sara Gonzales

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, Michael Mitsunaga certify that:

1. I have reviewed this Quarterly Report of Nunzia Pharmaceutical Company;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

8-12-2022 [Date]

/s/ Michael Mitsunaga

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

NUNZIA PHARMACEUTICAL COMPANY
UNAUDITED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTH
ENDED JUNE 30, 2022 AND 2021

NUNZIA PHARMACEUTICAL COMPANY		
CONSOLIDATED BALANCE SHEETS		
(Unaudited)		
	June 30,	December 31,
	2022	2021
ASSETS		
Current Assets		
Cash	\$ 72	\$ 131
Prepaid expenses	24,862	
Investment in related party	5,000	5,000
Total assets	<u>\$ 29,935</u>	<u>\$ 5,131</u>
LIABILITIES AND STOCKHOLDERS' DEFICIT		
Current liabilities		
Accounts payable and accrued liabilities	\$ 5,011	\$ 1,862
Related party notes payable	139,955	97,443
Total current liabilities	144,966	99,305
Total Liabilities	144,966	99,305
Commitments and contingencies	-	-
Stockholders' deficit		
Common stock; Class A, \$0.001 par value, 1,000,000,000 shares authorized, 434,189,578 and 244,369,578 shares issued and outstanding at June 30, 2021 and 2021, respectively	434,190	434,120
Common stock; Class B, \$0.001 par value, 100,000 shares authorized, 51,000 shares issued and outstanding at June 30, 2022 and December 31, 2021	51	51
Common stock payable	31,650	31,650
Additional paid-in capital	197,573,064	178,853,134
Accumulated deficit	(198,153,986)	(179,413,129)
Total stockholders' deficit	(115,031)	(94,174)
Total liabilities and stockholders' deficit	<u>\$ 29,935</u>	<u>\$ 5,131</u>
The accompanying notes are an integral part of the consolidated financial statements.		

NUNZIA PHARMACEUTICAL COMPANY				
CONSOLIDATED STATEMENTS OF OPERATIONS				
(Unaudited)				
	Three Months	Three Months	Six Months	Six Months
	Ended	Ended	Ended	Ended
	June 30,	June 30,	June 30,	June 30,
	2022	2021	2022	2021
Revenue	\$ -	\$ -	\$ -	\$ -
Operating expense				
General and administrative expense	17,727	6,629	36,112	22,277
General and administrative expense - related party		-	18,704,745	-
Total operating expense	17,727	6,629	18,740,856	22,277
Loss from operations	(17,727)	(6,629)	(18,740,856)	(22,277)
Other income (expense)	-	-	-	-
Net loss	\$ (17,727)	\$ (6,629)	\$ (18,740,856)	\$ (22,277)
Basic and Diluted Loss per Common Share	\$ (0.00)	\$ (0.00)	\$ (0.04)	\$ (0.00)
Weighted average number of common shares outstanding - basic and diluted	434,189,578	289,149,345	434,119,578	286,984,962
The accompanying notes are an integral part of the consolidated financial statements.				

NUNZIA PHARMACEUTICAL COMPANY CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021 (Unaudited)								
	Class A Common Stock		Class B Common Stock		Common stock	Additional Paid-in	Accumulated	Total
	Shares	Amount	Shares	Amount	Payable	Capital	Deficit	Stockholders'
Balance, December 31, 2020	244,369,578	\$ 244,370	\$ 51,000	\$ 51	\$ 9,040,400	\$ 92,006,134	\$ (101,354,159)	\$ (63,204)
Net loss							(15,648)	\$ (15,648)
Balance, March 31, 2021	244,369,578	\$ 244,370	\$ 51,000	\$ 51	\$ 9,040,400	\$ 92,006,134	\$ (101,369,807)	\$ (78,852)
Merger shares issued	17,750,000	17,750			(17,750)			
Return of merger shares issued in error	(9,000,000)	(9,000)			9,000			
Shares issued under sales and marketing agreement					5,000			5,000
Net loss							(6,629)	(6,629)
Balance, June 30, 2021	253,119,578	\$ 253,120	\$ 51,000	\$ 51	\$ 9,036,650	\$ 92,006,134	\$ (101,376,436)	\$ (80,481)
	Class A Common Stock		Class B Common Stock		Common stock	Additional Paid-in	Accumulated	Total
	Shares	Amount	Shares	Amount	Payable	Capital	Deficit	Stockholders'
Balance, December 31, 2021	434,119,578	\$ 434,120	\$ 102,000	\$ 51	\$ 31,650	\$ 178,853,134	\$ (179,413,129)	\$ (94,174)
Beneficial conversion features of related party note						18,685,000		18,685,000
Net loss							(18,723,130)	(18,723,130)
Balance, March 31, 2022	434,119,578	\$ 434,120	102,000	\$ 51	\$ 31,650	\$ 197,538,134	\$ (198,136,259)	\$ (132,304)
Common shares issued in a private placement	70,000	70				34,930		34,930
Net loss							(17,727)	(17,727)
Balance, June 30, 2022	434,189,578	\$ 434,190	102,000	\$ 51	\$ 31,650	\$ 197,573,064	\$ (198,153,986)	\$ (115,031)

NUNZIA PHARMACEUTICAL COMPANY		
CONSOLIDATED STATEMENTS OF CASH FLOWS		
(Unaudited)		
	Six Months	Six Months
	Ended	Ended
	June 30,	June 30,
	2022	2021
Cash flows from operating activities		
Net loss	\$ (18,740,856)	\$ (22,277)
Adjustments to reconcile net loss to net cash flows from operating activities		
Stock based compensation expense	18,685,000	-
Changes in operating assets and liabilities:	-	126
Prepaid expenses	(24,862)	(2,500)
Accounts payable	3,148	-
Net cash flows from operating activities	\$ (77,571)	(24,651)
Cash flows from financing activities		
Private placement of common stock	35,000	
Increase in related party notes payable	42,512	26,154
Net cash flows from financing activities	77,512	26,154
Change in cash	\$ (59)	1,503
Cash at beginning of period	131	-
Cash at end of period	\$ 72	\$ 1,503
Supplemental disclosure of cash flow information:		
Interest paid in cash	\$ -	\$ -
Income taxes paid in cash	\$ -	\$ -
The accompanying notes are an integral part of the consolidated financial statements		

NUNZIA PHARMACEUTICAL COMPANY

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – Basis of Presentation, Organization, Going Concern and Recent Accounting Pronouncements

Basis of Presentation

The accompanying unaudited interim consolidated financial statements of Nunzia Pharmaceutical Company (the “**Company**”) as of March 31, 2022 and 2021 have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”), for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted.

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Actual results may differ from those estimates. The interim financial statements should be read in conjunction with the unaudited financial statements and notes thereto included in the Company’s Annual Report for the year ended December 31, 2021.

Organization

Nunzia Pharmaceutical Company (the “Company”), was incorporated on November 12, 1986, in the state of Utah under the name of Silver Harvest, Inc. In February 1990, the Company amended its Articles of Incorporation to change its name to Viking Capital Group, Inc. In June 2010, the Company amended its Articles of Incorporation to change its name to its name to Arizona Gold and Onyx Mining Company. On February 1, 2018, the Company amended its Articles of Incorporation to change its name to Nunzia Pharmaceutical Corporation in anticipation of completion of a merger with Cal-Biotech, Inc. (A Wyoming Corporation), owner of www.NunziaPharmaceutical.com.

On October 22, 2017, the Company and Cal-Biotech, Inc. (“Cal-Biotech”) entered into a Merger and Consolidation Agreement (the “MCA”). In anticipation of closing on the MCA, on February 1, 2018, the Board authorized a 7,000:1 reverse stock split, which took effect on December 4, 2019, and amended its articles changing its name to Nunzia Pharmaceutical Company. On December 13, 2020, the Company agreed to issue 284,500,000 shares pursuant to MCA (the “MCA Shares”). Of the shares issued, 1) 248,270,000 were to be issued to LionsGate Funding Group LLC (“LionsGate”) (majority owner of Cal-Biotech) in exchange for the all the issued and outstanding stock in Cal-Biotech and to settle \$156,657 of advances from Cal-Biotech to the Company that were originally funded by LionsGate; and 2) 36,230,000 were issued to settle \$144,570 of debt and advances recorded as liabilities to related and non-related parties.

The Company is focused on manufacturing and securing retail space for its nutraceutical products. It is also working on a product that kills bacteria and viruses. The Company’s efforts have been delayed due to the onset and lingering impact of Covid -19 as well as the lack of significant available funding.

The Company’s year end is December 31st.

Going Concern

The Company’s financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs to allow it to continue as a going concern. As of June 30, 2022, the Company had an accumulated deficit of \$198,153,986. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

In view of these conditions, the ability of the Company to continue as a going concern is in doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. Historically, the Company has relied upon internally generated funds and funds from the sale of shares of stock, issuance of promissory notes and loans from its shareholders and private investors to finance its operations and growth. Management is planning to raise necessary additional funds for working capital through loans and/or additional sales of its common stock. However, there is no assurance that the Company will be successful in raising additional capital or that such additional funds will be available on acceptable terms, if at all. Should the Company be unable to raise this amount of capital its operating plans will be limited to the amount of capital that it can access. These financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying financial statements.

NOTE 2 – Summary of Significant Accounting Policies

Principles of Consolidation

These consolidated financial statements presented are those of the Company and its wholly owned subsidiaries, A1 Mining; NIAI Insurance Administrators, Inc. of California; Viking Capital Financial Services, Inc. of Texas; Viking Insurance Services, Inc. of Texas; Viking Systems, Inc. of Texas; Viking Administrators, Inc. of Texas; Viking Capital Ventures, Inc. of Texas; and 60% of Brentwood Re, Ltd. of the Island of Nevis. All subsidiaries have had their charters suspended or revoked and have been inactive for several years.

Management's Representation of Interim Financial Statements

The accompanying unaudited consolidated financial statements have been prepared by the Company without audit pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States ("GAAP") have been condensed or omitted as allowed by such rules and regulations, and management believes that the disclosures are adequate to make the information presented not misleading. These consolidated financial statements include all of the adjustments, which in the opinion of management are necessary to a fair presentation of financial position and results of operations. All such adjustments are of a normal and recurring nature. Interim results are not necessarily indicative of results for a full year. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements at and as of December 31, 2021, filed as part of the Company's Annual Report on Form 10-K with the SEC on April 15, 2022.

Accounting estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires Management to make estimates and assumptions that affect the reported amounts of stock based compensation, assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from those estimates.

Cash and cash equivalents

The Company considers all highly liquid instruments purchased with an original maturity of three months or less and money market accounts to be cash equivalents. As of June 30, 2022 and December 31, 2021, we had \$72 and \$131 in cash on hand, respectively.

Income Taxes

The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences and carry-forwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized. The Company reports a liability for unrecognized tax benefits resulting from uncertain income tax positions, if any, taken or expected to be taken in an income tax return. Estimated interest and penalties are recorded as a component of interest expense or other expense, respectively.

Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company utilizes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:

Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;

Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

During the periods covered by this report, the Company did not have any assets or liabilities that were required to be measured at fair value on a recurring basis or on a non-recurring basis.

Fair Value of Financial Instruments

The Company's financial instruments consist of accounts payable and accrued expenses. The carrying amounts of the Company's financial instruments approximate fair value because of the short-term maturity of these items. These fair value estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect those estimates. We do not hold or issue financial instruments for trading purposes, nor do we utilize derivative instruments.

Stock-Based Compensation

The Company accounts for stock-based compensation in accordance with Accounting Standards Codification ("ASC") 718, Stock Based Compensation. ASC 718 requires all stock-based payments to directors, employees and consultants, including grants of stock options, to be recognized in the consolidated statements of operations based on their fair values. If a stock-based award contains performance-based conditions, at the point that it becomes probable that the performance conditions will be met, the Company records a cumulative catch-up of the expense from the grant date to the current date, and then amortizes the remainder of the expense over the remaining service period. Management evaluates when the achievement of a performance-based condition is probable based on the expected satisfaction of the performance conditions as of the reporting date.

Net Income (Loss) Per Share

The computation of basic earnings per share ("EPS") is based on the weighted average number of shares that were outstanding during the period, including shares of common stock that are issuable at the end of the reporting period. The computation of diluted EPS is based on the number of basic weighted-average shares outstanding plus the number of common shares that would be issued assuming the exercise of all potentially dilutive common shares outstanding using the treasury stock method. The Company had no potentially dilutive securities as of March 31, 2021 and December 31, 2021.

Recent accounting pronouncements not yet adopted

In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, Income Taxes – Simplifying the Accounting for Income Taxes. The guidance removes certain exceptions for recognizing deferred taxes for equity method investments, performing intra period allocation, and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for goodwill and allocating taxes to members of a consolidated group, among others. This guidance is effective for interim and annual reporting periods beginning after December 15, 2020. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The transition requirements are dependent upon each amendment within this update and will be applied either prospectively or retrospectively. The adoption of ASU 2019-12 is not expected to have a material impact on the Company's consolidated financial position, results of operations, or cash flows.

In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2020-06, "Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity" ("ASU 2020-06"), which simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for the Company for fiscal years beginning after December 31, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020 and adoption must be as of the beginning of the Company's annual fiscal year. The Company adopted ASU 2020-06 beginning with our fiscal year starting on January 1, 2021.

Recent Adopted Accounting Pronouncements

The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company's previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion. The Company believes that none of the new standards will have a significant impact on the financial statements.

NOTE 3 – Preferred and Common Stock

Preferred Stock

The Company has Preferred stock: \$1.00 par value; 50,000,000 shares authorized with no shares issued and outstanding.

Common Stock

The Company has 51,000 shares of Class B Common Stock issued and outstanding as of March 31, 2022. The Class B shares are the only shares eligible to vote for Directors. LionsGate, controlled by the Company's CEO, holds all Class B common shares.

The Company has 1,000,000,000 shares of Class A Common Stock authorized of which 434,189,578 and 434,119,578 shares are issued and outstanding as of March 31, 2022 and December 31, 2021, respectively.

NOTE 4 – Commitments and Contingencies

COVID-19 Pandemic and the Coronavirus Aid, Relief, and Economic Security ("CARES") Act

On January 30, 2020, the World Health Organization ("WHO") announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the "COVID-19 outbreak") and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally.

The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude that the pandemic may have on the Company's financial condition, liquidity, and future results of operations. Management is actively monitoring the impact of the global situation on its financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, the Company is not able to estimate the effects of the COVID-19 outbreak on its results of operations, financial condition, or liquidity for fiscal year 2022.

The pandemic may adversely affect our operations, our employees and our employee productivity. It may also impact the ability of our subcontractors, partners, and suppliers to operate and fulfill their contractual obligations, and result in an increase in costs, delays or disruptions in performance. Our employees are working remotely and using various technologies to perform their functions. In reaction to the spread of COVID-19 in the United States, many businesses have instituted social distancing policies, including the closure of offices and worksites and deferring planned business activity. The disruption and volatility in the global and domestic capital markets may increase the cost of capital and limit our ability to access capital. Both the health and economic aspects of the COVID-19 virus are highly fluid and the future course of each is uncertain. For these reasons and other reasons that may come to light if the coronavirus pandemic and associated protective or preventative measures expand, we may experience a material adverse effect on our business operations, revenues and financial condition; however, its ultimate impact is highly uncertain and subject to change.

On March 27, 2020, then President Trump signed into law the CARES Act. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property. The CARES Act also appropriated funds for the SBA Paycheck Protection Program loans that are forgivable in certain situations to promote continued employment, as well as Economic Injury Disaster Loans to provide liquidity to small businesses harmed by COVID-19.

NOTE 5 – Transactions with Related Persons

Mr. Michael Mitsunaga, our President and Director, has made interest-bearing advances to the Company at an interest rate of 8% commencing on October 1, 2021. As of June 30, 2022 and December 31, 2021 the principal balance due to Mr. Mitsunaga was \$139,955 and \$97,433, respectively. Accrued interest on the same dates was \$5,011 and \$1,862, respectively. During the three month ended March 31, 2022 pursuant to the terms of a Promissory Note with the Company, Mr. Mitsunaga advanced \$35,000 to the Company to help fund its operation. Mr. Mitsunaga has the right to convert that \$35,000 loan (including in the balance of \$139,955 above) in 36,000,000 shares of the Company's common stock. On March 4, 2022 when the Promissory Note was executed the trading price of the Company's common stock was \$0.52. As a result the company record stock based compensation, related party of \$18,685,000 on its statement of operations.

NOTE 6 – Subsequent Events

Management has reviewed material events subsequent of the period ended March 31, 2022 and prior to the filing of financial statements in accordance with FASB ASC 855 "Subsequent Events".